All articles by Janet Beal

UK’s antibiotic subscription funding model – a route to market sustainability?

On 8 May, the UK was the first government in the world to formally implement a groundbreaking new model for…
VPAS is dead, long live VPAG—could the UK’s new clawback revision save the day?

After months of intense negotiations, the UK Department of Social Care (DHSC) and the Association of the British Pharmaceutical Industry…
The VPAS fallout continues – Celltrion pulls high-profile biosimilar from UK market

The punitive 2023 payback rate from the UK Government’s Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) has triggered…
Pharma sector reels as UK Government doubles VPAS payback rate on NHS drugs

The UK government’s decision to set an unprecedented payback rate of 26.5% on National Health Service (NHS) sales of branded…
Ukraine’s healthcare system – resilience under fire

As the Ukrainian population takes cover and entrenches its resistance to the Russian invasion, Ukraine's health minister Viktor Lyashko has…

The UK’s first drug approval via Project Orbis – pulling away from the EMA strings?

In early May, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) approved a targeted anticancer drug, AstraZeneca's Tagrisso (osimertinib),…
UK bans parallel export of two COVID-19 treatment candidates to protect national supply

While the UK has not yet seen a major cluster of infections in the current major international outbreak of coronavirus…
Zolgensma may be a potential game-changer for SMA

Within the next month, the US Food and Drug Administration (FDA) is set to review a landmark gene therapy product,…
So, was this worth the wait?…the UK government finally responds to last year’s Accelerated Access Review

It has taken a while, but at long last the UK government has issued its much-anticipated response to the Accelerated Access…
Time for a consultation on the impact of Brexit on the UK’s access to medicines: Better late than never?

In a move which might best be described with the understatement "well, about time…", the UK's cross-parliamentary select committee on…